General Proximity GTM brain

General Proximity develops induced-proximity medicines and partners with pharmaceutical researchers on difficult drug targets.

category

Induced-proximity drug discovery

market profile

  • text: Discovery partnerships are a potential route to advance previously difficult targets alongside an internal therapeutics pipeline.
  • text: Induced proximity spans more mechanisms than protein degradation alone, creating room for differentiated effector discovery.

personas

  • title: Pharma head of oncology discovery
    pains:
    • Important disease targets resist conventional inhibition.
    • Teams need experimental evidence that novel mechanisms translate into viable drug candidates.
  • title: Pharma business development and licensing leader
    pains:
    • Finding differentiated external platforms for high-value targets.
    • Assessing partnership rights, program milestones and platform validation.

icp

  • text: Large pharmaceutical companies with discovery and external innovation teams pursuing hard-to-drug targets.
  • text: Research institutions and cancer centers with relevant target biology and translational programs.

message pillars

  • text: Position the platform as a general discovery engine rather than one mechanism.
  • text: Explain proximity as a way to control biology.
  • text: Focus on targets beyond conventional medicine's reach.

objections

  • objection: Can a new proximity mechanism produce a viable drug?
    response: Evaluate target-specific experimental data, selectivity and development plans in diligence; the platform claim alone is not clinical proof.
  • objection: Why use this approach instead of an established degrader?
    response: Explore whether non-degradation effector mechanisms fit the target biology, then compare experimentally.

competitors

  • name: Arvinas
    why: Develops targeted protein degradation medicines using induced proximity.
  • name: Cedilla Therapeutics
    why: Drug discovery company pursuing difficult targets and differentiated mechanisms.

influencers

  • name: Armand Cognetta
    url: https://www.linkedin.com/in/armandcognetta
    why: Founder and CEO discussing the company and hiring.

keywords

  • induced proximity drug discovery
  • molecular glue therapeutics
  • undruggable targets
  • targeted protein degradation
  • proximity therapeutics
  • effector protein discovery

voice

  • scientific and mechanism-led
  • ambitious
  • confident

signals

  • text: Pharma announces an oncology discovery collaboration or searches for external platform partners.
  • text: A discovery team has target proteins poorly served by existing inhibitors.

pricing

model: unknown

motion

sales_led

channels

  • LinkedIn
  • scientific partnerships

confidence

medium

Founders

  • name: Armand Cognetta
    title: Founder
    role: Founder
    bio: Armand completed his PhD in Chemical Biology at the Scripps Research Institute under the supervision of Dr. Benjamin F. Cravatt. There he co-authored 19 scientific publications in prestigious journals such as Cell, Nature, and Science, as well as multiple patents, including a portion of the foundational IP for Abide Therapeutics (acq. Lundbeck) and Vividion Therapeutics (acq. Bayer). Prior to founding GP he was an early employee at the Flagship Pioneering start-up Inzen Tx (now Sonata).

Back to YC companies